Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis has concluded patient recruitment in first low dose cohort in a Phase II trial to evaluate ADXS-HPV in patients with cervical intraepithelial neoplasia (CIN).
Subscribe to our email newsletter
The placebo controlled, randomized and single blind trial is intended to investigate the safety and efficacy o f ADXS-HPV in around three different dose cohorts.
The company expects to release the low dose results in early 2012.
Advaxis chairman /CEO Thomas Moore said the six-month follow-up evaluation for this cohort will be completed by this January.
"The mid-dose leg will begin recruitment immediately," Moore said.